Serine esterase and hemolytic activity in human cloned cytotoxic T lymphocytes.

Target cell lysis by most murine cytotoxic T lymphocytes appears to be mediated by a complement (C9)-like protein called perforin, contained in high-density cytoplasmic granules. These granules also contain high levels of serine esterase activity, which may also play a role in cytolysis. Analysis of 17 cloned human cytotoxic T lymphocytes revealed the presence of serine esterase that is very similar to its murine counterpart in substrate and inhibitor specificities, pH optimum, and molecular mass; dot blot hybridization with synthetic oligonucleotides corresponding to the active sites of two known murine CTL esterases suggests homology to the murine enzyme HF. However, serine esterase was present at only approximately 10% of the level found in murine CTLs, and was not secreted during CTL-target cell interaction; moreover, hemolytic activity could not be detected in any of the seven cell lines tested. The results suggest that the human CTLs examined here kill their target cells by a mechanism different from that used by most cloned murine CTLs.

Tissue-specific expression of functionally rearranged lambda 1 Ig gene through a retrovirus vector.

To explore the potential use of retrovirus vectors for the transfer of genomic DNA sequences into mammalian cells, recombinant retroviral genomes were constructed that encode a functionally rearranged murine lambda 1 immunoglobulin gene. Several of these genomes could be transmitted intact to recipient cells by viral infection, although successful transmission depended both on the orientation of the lambda 1 sequences and on their specific placement within vector sequences. The lambda 1 gene transduced by viral infection was expressed in a cell lineage-specific manner, albeit at lower levels than endogenous lambda 1 gene expression in cells from the B-lymphocyte lineage. Vectors yielding integrated proviruses that lacked viral transcriptional enhancer sequences were used to show that neither viral transcription nor the viral transcriptional sequences themselves had any effect on the tissue specificity of lambda 1 gene expression or the absolute amount of lambda 1 transcription. Vector transcription did, however, dramatically decrease the amount of lambda 1 protein that could be detected in tranduced cells. These results suggest that retrovirus vectors may be useful reagents not only for the expression of complementary DNA sequences but also for studies of tissue-specific transcription in mammalian cells.

The use of microcapsules for high density growth of human tumor infiltrating lymphocytes and other immune reactive T cells.

The use of microcapsules to achieve high density growth of tumor infiltrating lymphocytes (TIL) and other antigen-specific human T cells is described. Whereas human T cells in suspension cultures usually do not exceed 1-2 x 10(6) cells/ml, densities approaching that found in living tissues (greater than 10(8) cells/ml) have been observed for microcapsule cultures. TIL and human peripheral blood-derived T cells can be routinely recovered from microcapsules with viabilities greater than or equal to 90%. The recovered cells retain their antigen reactivities and bear cell surface phenotypes identical to their counterparts grown in suspension culture. These findings suggest that microcapsule technology could prove valuable in generating the vast numbers of cells required for TIL therapy and other forms of adoptive immunotherapy with T cells.

Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.

The interaction between leukocyte function-associated antigen-1 (LFA-1) and intracellular adhesion molecule-1 (ICAM-1) has been implicated in inflammatory and immune diseases. Recently, a novel series of p-arylthio cinnamides has been described as potent antagonists of the LFA-1/ICAM-1 interaction. These compounds were found to bind to the I domain of LFA-1 using two-dimensional NMR spectroscopy of 15N-labeled LFA-1 I domain. On the basis of NOE studies between compound 1 and the I domain of LFA-1, a model of the complex was constructed. This model revealed that compound 1 does not directly inhibit ICAM-1 binding by interacting with the metal ion dependent adhesion site (MIDAS). Instead, it binds to the previously proposed I domain allosteric site (IDAS) of LFA-1 and likely modulates the activation of LFA-1 through its interaction with this regulatory site. A fragment-based NMR screening strategy was applied to identify small, more water-soluble ligands that bind to a specific region of the IDAS. When incorporated into the parent cinnamide template, the resulting analogues exhibited increased aqueous solubility and improved pharmacokinetic profiles in rats, demonstrating the power of this NMR-based screening approach for rapidly modifying high-affinity ligands.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.

The interaction between leukocyte function-associated antigen-1 (LFA-1), a member of the beta(2)-integrin family of adhesion molecules, and intracellular adhesion molecule ICAM-1 (cd54) is thought to play a critical role in the inflammatory process. On the basis of an anilino diaryl sulfide screening lead 1, in combination with pharmacophore analysis of other screening hits, we have identified an adjacent binding pocket. Subsequently, a p-ethenylcarbonyl linker was discovered to be optimal for accessing this binding site. Solution-phase parallel synthesis enabled rapid optimization of the cinnamides for this pocket. In conjunction with fine-tuning of the diaryl substituents, we discovered a novel series of potent, nonpeptide inhibitors of LFA-1/ICAM-1 interaction, exemplified by A-286982 (28h), which has IC(50) values of 44 and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide.

We have shown that p-arylthio cinnamides can inhibit the interaction of LFA-1 and ICAM-1, which is involved in cell adhesion and the inflammatory process. We now show that 2,3-disubstitution on the aryl portion of the cinnamide results in enhanced activity over mono substitution on the ring. The best 2,3-substituents were chlorine and trifluoromethyl groups. Compounds 39 and 40 which contain two CF3 groups have IC(50) values of 0.5 and 0.1 nM, respectively, in inhibiting JY8 cells expressing LFA-1 on their surface, from adhering to ICAM-1. The structure-activity relationship (SAR) was examined using an NMR based model of the LFA-1 I domain/compound 31 complex. One of our compounds (38) was able to reduce cell migration in two different in vivo experiments.

Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides.

The interaction of LFA-1 and ICAM-1 plays an important role in the cell adhesion process. On the basis of previously reported SAR and structural information on the binding of our p-arylthiocinnamide series to LFA-1, we have identified the cyclic amide (C-ring) as a site for modification. Improvement in potency and, more importantly, in the physical properties and pharmacokinetic profiles of the leading compounds resulted from this modification. One of the best compounds (11f) is also shown to reduce myocardial infarct size in rat.

Dissolution rate of cholesterol and palmitic acid mixtures in cholelitholytic cosolvent systems.

The dissolution rates and solubilities of cholesterol monohydrate, palmitic acid, and their mixtures in the cholelitholytic solvents monooctanoin (MO) and methyl tert-butyl ether (MTBE) and mixtures of these two solvents were determined. The dissolution rates obtained were consistent with the diffusion-controlled two-component noninteracting model. The addition of MTBE as cosolvent to MO resulted in an increase in the solubility of both cholesterol monohydrate and palmitic acid; in the case of the former, the solubility peaked at 80% MTBE. Neither solute exhibited a log-linear solubility relationship on addition of MTBE as cosolvent. Furthermore the increases in the dissolution rates of both components were much larger than could be explained by the solubility increases alone. Mass transfer coefficients increased dramatically with increasing MTBE content of the solvent, were consistently higher for palmitic acid, and reflected the decline in solvent viscosity. Incorporation of relationships among solubility, viscosity, and cosolvent composition into the two-component noninteracting model gave good correlation between predicted and observed rates over nearly 3 orders of magnitude.

Increased tumor-specific CTL activity in human tumor-infiltrating lymphocytes stimulated with autologous tumor lines.

Two long-term tumor-infiltrating lymphocyte (TIL) lines and their autologous tumor lines have been established from solid tumors derived from different patients with metastatic melanoma. In 4-hr 51Cr release assays, each TIL culture lysed only the autologous cryopreserved fresh or established melanoma line, but failed to lyse other melanoma tumors or K562 cells. Repeated stimulation of TIL with the autologous melanoma lines resulted in significant increases in anti-tumor CTL activity with no apparent loss in specificity. Stimulated cells have retained cytotoxic activity for up to 5 months in culture. Tumor cell CTL activity for both long-term TIL lines is inhibited by several mAbs, including those against CD3, CD8, and class I MHC molecules, indicating that the effector cells are class I-restricted CD8+, CTL. Furthermore, recognition of Ag on one of the established melanoma lines by TIL is restricted by HLA A-2. The availability of autologous tumor lines may prove clinically useful for the selective stimulation and expansion of cells with anti-tumor activity within a heterogeneous TIL population.

GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes.

GD3 is expressed in high concentrations on melanoma cells and may serve as a useful target antigen for mAb-mediated immunotherapy. Monoclonal antibodies (mAbs) against GD3 stimulate cell-mediated immune responses against tumor cells in vitro and this activity may contribute to antitumor effects in patients with melanoma treated with GD3-reactive mAbs. In the present study the effects of GD3-reactive mAbs on autologous tumor cell lysis by a human melanoma-derived tumor-infiltrating lymphocyte (TIL) population were examined. Unlike results reported for other GD3+ T cells isolated from melanoma patients, the tumor-specific lytic activity of the TIL line was inhibited by incubation with mAbs against GD3. Other melanoma-reactive mAbs, including those against GD2 and the high-molecular-weight melanoma-associated Ag, had no effect on the TIL lytic activity. Overall, these results indicate that mAbs against GD3 may have different effects on T cell/tumor cell interactions.

Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.

A line of tumor-infiltrating lymphocytes (660TIL) specifically lysed the autologous HLA-A2+ melanoma (660MEL) and also most A2+ melanoma cell lines. We immunoprecipitated A2 from a large number (>10(12)) of 660MEL cells, extracted naturally processed peptides, fractionated them by HPLC, screened the fractions for recognition by 660TIL, and found a single predominant and a minor peak of activity. Although too little was recovered of the major 660MEL peptide to establish its sequence, HPLC fingerprinting showed that it did not correspond to any of the known A2-associated melanoma peptides recognized by T cells, including peptides from tyrosinase, MART-1/Melan-A, gp100 and MAGE-3. The major 660MEL antigenic peptide appears to be derived from MART-1/Melan-A but is neither AAGIGILTV nor ILTVILGVL nor any other MART-1/Melan-A peptide containing the A2 consensus motif. The multiplicity of melanoma peptides recognized by CD8+ T cells, most of which are non-mutated (including most likely the present 660MEL peptide), suggests the existence of unknown mechanisms, perhaps similar to those operating in autoimmune disorders, whereby T cells that recognize normal 'self' sequences become activated.

Synthesis of lambda 1, lambda 2, and lambda 3 light chains by mouse spleen B cells.

To determine whether the infrequency of immunoglobulins with lambda 3 light chains is due to a corresponding scarcity of lambda 3 B cells, the production of the various lambda chain subtypes (lambda 1, lambda 2, and lambda 3) by normal spleen cells was compared. The results showed that lambda 1, lambda 2, and lambda 3 chains are produced in a ratio of about 1.0: 0.7 : 0.3, respectively. The argument is made that lambda 1, lambda 2, and lambda 3 B cells exist in the same ratio. Results obtained with neonatal and nude mouse spleen cells suggest that these small differences are not due to stimulatory effects of environmental antigens or regulatory T cells. The much greater disparity in the abundance of lambda subtypes in various antibody responses and serum Ig suggests that lambda 1 B cells may be more likely than lambda 2 or lambda 3 B cells to differentiate into antibody-secreting plasma cells.

Synthesis of lambda light chain subtypes by stimulated and unstimulated mouse B cells.

Inbred mouse make 3 lambda chain subtypes. The lambda 1 and lambda 3 chains have similar variable (V) regions (in both the same V gene segment [V lambda 1] is used), whereas lambda 2 and lambda 3 have similar constant (C) regions. Despite the lambda 1 and lambda 3 V region similarity, lambda 1 occurs much more frequently than lambda 3 (and lambda 2) in the serum immunoglobulins and antibody responses of most inbred strains of mice. To explore the basis for the lambda 1 predominance, we compared the rates of synthesis of the 3 subtypes and the frequencies of the B cells that synthesize them, focussing on "resting" (i.e., unstimulated) and on polyclonally stimulated B cells from spleens of unimmunized BALB/c mice. In resting cells the relative rates of synthesis and the relative frequencies of the respective B cells were in accord, indicating that the rate of lambda chain synthesis is approximately the same per resting B cell, regardless of the lambda subtype it produces. However, in the polyclonally stimulated cells, lambda 1 was made 7 times faster than lambda 2 and 10 times faster than lambda 3; normalizing these rates by the frequencies of the respective stimulated cells suggests that in stimulated B cells lambda 1 chains are made 5 times faster per cell than lambda 2 or lambda 3, while the latter are made at about the same rate per cell. In view of the marked structural homology between lambda 2 and lambda 3 genes in segments other than the V-gene segment, we suggest that the pronounced differences among polyclonally stimulated B cells in expression of the genes for the various lambda subtypes may be due to the presence of less potent enhancer-like sequences in the lambda 2 and lambda 3 genes than in the lambda 1 gene.

A functional gamma gene formed from known gamma-gene segments is not necessary for antigen-specific responses of murine cytotoxic T lymphocytes.

Structural similarities between surface immunoglobulins (s Ig) on B cells and antigen-specific receptors on T cells suggest that a T cell, like a B cell, should express only two immunoglobulin-like genes, one for each subunit of the disulphide-linked, heterodimeric, antigen-specific (alpha beta) T-cell receptor. However, cytotoxic T lymphocytes (Tc cells) and immature thymocytes also contain RNA transcripts of a third immunoglobulin-like gene, called gamma (refs 1-4). A polypeptide corresponding to the gamma gene has not yet been identified and the function of this gene remains an enigma. Judging from its nucleotide sequence, the rearranged gamma gene is expected to encode an integral membrane polypeptide chain, and gamma complementary DNAs from two cloned Tc cell lines have previously been found to have different sequences around the V-J (variable region-joining region) junction, suggesting that, in these cells, the gamma-gene product is a clonally diverse surface structure that may form part of an as yet unidentified, antigen-specific receptor. To analyse further the extent of diversity of the gamma-gene product, we have determined the partial sequences of 11 gamma cDNA clones from three other cloned Tc cell lines, and report here that the sequences are indeed clonally diverse, but in all instances they are out-of-phase in the region of the V-J junction. This finding and the pattern of gamma-gene rearrangements in these cell lines indicate that a polypeptide product of the previously reported gamma gene, V2J2-C2, is not expressed in them and is, therefore, not necessary for the antigen-specific cytotoxic and proliferative responses of these mature T cells.

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

A genetically engineered fusion protein consisting of a chimeric anti-ganglioside GD2 antibody (ch14.18) and interleukin 2 (IL2) was tested for its ability to enhance the killing of autologous GD2-expressing melanoma target cells by a tumor-infiltrating lymphocyte line (660 TIL). The fusion of IL2 to the carboxyl terminus of the immunoglobulin heavy chain did not reduce IL2 activity as measured in a standard proliferation assay using either mouse or human T-cell lines. Antigen-binding activity was greater than that of the native chimeric antibody. The ability of resting 660 TIL cells to kill their autologous GD2-positive target cells was enhanced if the target cells were first coated with the fusion protein. This stimulation of killing was greater than that of uncoated cells in the presence of equivalent or higher concentrations of free IL2. Such antibody-cytokine fusion proteins may prove useful in targeting the biological effect of IL2 and other cytokines to tumor cells and in this way stimulate their immune destruction.